Search

Background: Degloving skin and soft-tissue injury (DSTI) is a kind of serious lesion in the field of surgery, with potential risk of morbidity and mortality. This study is aimed to summarize and analyze the current situation of DSTI in China, so as to provide enlightenments for better prevention and treatment. Methods: By searching inpatients’ information on the first page recorded by the Hospital Quality Monitoring System from January 1, 2013 to December 31, 2018, patients diagnosed with DSTI were identified and screened based on the International Classification of Diseases coding System. Demographic characteristics, injury and cost information were collected for analysis. Results: There were 62709 patients who were diagnosed with DSTI, of whom 67.41% were males with a mean age of 43.01±19.70. Peasants and workers, traffic-related accidents and falls, summer and autumn accounted for high percentage of the study indicators. The operation rate of DSTI roughly showed a growing trend, and the average length of stay was 22.02±29.73 days, during which time 0.93% of the patients ended up in death. Medicine took up the first place of the hospitalization expense, but was decreasing year by year, while the proportion of other expenses gradually increased. More than half of the patients paid at their own charge, but the ratio of urban medical insurance was rising. The most and least frequent anatomic site of DSTI were lower extremity (43.40%) and torso (1.59%). Each injury site showed its own characteristics. Conclusions: This is the first retrospective study that targeted a nationwide data bank to make a relatively detailed epidemiological analysis of DSTIs from 2013 to 2018 in China. From this work, not only a preliminary understanding but also enlightenments for better prevention and treatment of DSTI has been gained.

BACKGROUND: Bone marrow-derived mesenchymal stem cells (BMSCs) have been shown to have some beneficial effects in acute lung injury (ALI), but the therapeutic effects are limited due to apoptosis or necrosis after transplantation into injured lungs. Here, we aim to explore whether Non-muscle myosin II (NM-II) knockdown could enhance BMSCs survival and improve therapeutic effects in ALI. METHODS: MSCs, isolated from rat bone marrow, were transfected with the small interfering RNA (siRNA) targeted to NM-II mRNA by a lentivirus vector. Rats were equally randomized to four groups: the control group was given normal saline via tail vein; the other three groups underwent intratracheal lipopolysaccharide (LPS) instillation followed by administration with either normal saline, BMSCs transduced with lentivirus-enhanced green fluorescent protein (eGFP) empty vector, or BMSCs transduced with lentivirus-eGFP NM-II siRNA. Hematoxylin and eosin staining was used to evaluate lung histopathologic changes and Masson trichrome staining was used to assess lung fibrosis. The myeloperoxidase activity was also tested in lung tissues. The mRNA expression of inflammatory cytokines in lung tissues was determined via quantitative reverse transcription PCR. Sex-determining region of the Y chromosome gene expression was measured by fluorescence in situ hybridization (FISH) assay. The expression of self-renewal activity and apoptosis-associated proteins were measured by Western blot. RESULTS: Transplantation of NM-II siRNA-modified BMSCs could improve histopathological morphology, decrease inflammatory infiltrates, down-regulate the expression levels of inflammatory cytokines, and reduce pulmonary interstitial edema. NM-II siRNA-modified BMSCs showed antifibrotic properties and alleviated the degrees of pulmonary fibrosis induced by endotoxin. In addition, NM-II knockdown BMSCs showed slightly better therapeutic effect on lung inflammation when compared with control BMSCs. The beneficial effects of NM-II siRNA-modified BMSCs may be attributed to enhanced self-renewal activity and decreased apoptosis. CONCLUSIONS: NM-II knockdown could inhibit the apoptosis of implanted BMSCs in lung tissues and improve its self-renewal activity. NM-II siRNA-modified BMSCs have a slightly enhanced ability to attenuate lung injury after LPS challenge.